Mike Smith, Author at

(651)-GIL-SP1-Cell-Therapy-Leadership-videos-BOTH-Feature-NEW

In these videos, Markwin Velders and Louis van de Wiel of Kite, a Gilead Company, provide a behind

Building cell therapy leadership in Europe

https://pharmaphorum.com/video/building-cell-therapy-leadership-europe/

9th EPP Life Sciences Pricing Forum

Mike Smith data, Life Sciences, pricing, smart data 0 Comment

Date: October 14-16 Location: Munich ,Germany Summary: The 9th annual EPP Life Sciences Pricing Forum will provide you with the

9th EPP Life Sciences Pricing Forum

https://pharmaphorum.com/events/9th-epp-life-sciences-pricing-forum/

Patients/ Views & Analysis/ Views and analysis

Building our own community for an ultra-rare disease

Mike Smith patient groups, patient insights, ultra-rare disease 0 Comment

Bo Bigelow shares the story of his daughter Tess, who has an ultra-rare genetic disorder with only 51

Building our own community for an ultra-rare disease

https://pharmaphorum.com/views-and-analysis/building-our-own-community-for-an-ultra-rare-disease/

Magnifying Glass on digital fingerprint background. 3d illustration

Future of Generics/ Views and analysis

The Falsified Medicines Directive – truly an opportunity for pharma?

Mike Smith Accord Healthcare, Falsified Medicines Directive, FMD 0 Comment

Telling the fake from the true is often a challenge, particularly in this era of ‘fake news’. But,

The Falsified Medicines Directive – truly an opportunity for pharma?

https://pharmaphorum.com/spotlight/future-of-generics/falsified-medicines-directive-opportunity-pharma/

Views and analysis

Spotlight on the future of generics

Mike Smith Accord Healthcare, generics, healthcare 0 Comment

Generic drugs play a vital role in ensuring affordable access to healthcare and the future sustainability of medicines

Spotlight on the future of generics

https://pharmaphorum.com/views-and-analysis/spotlight-future-generics-accord-healthcare/

ASCO 2019 and the future of oncology/ Oncology/ Views & Analysis/ Views and analysis

ASCO 2019 round-up

Mike Smith ASCO 2019, kantar, Oncology 0 Comment

With the American Society of Clinical Oncology (ASCO) conference over for another year, Richard Staines presents a round-up

ASCO 2019 round-up

https://pharmaphorum.com/spotlight/asco-2019-and-the-future-of-oncology/asco-2019-round-up/

ASCO 2019 and the future of oncology/ Video/ Views & Analysis/ Views and analysis

ASCO 2019 – Kantar takes a first look at interim data from the Phase 3 TITAN trial

Mike Smith ASCO 2019, kantar, Oncology 0 Comment

Will Erleada take the lead in metastatic CSPC? New interim data at ASCO 2019 from the Phase 3

ASCO 2019 – Kantar takes a first look at interim data from the Phase 3 TITAN trial

https://pharmaphorum.com/spotlight/asco-2019-and-the-future-of-oncology/asco-2019-kantar-interim-data-phase-3-titan-trial/

ASCO 2019 and the future of oncology/ Oncology/ Views & Analysis/ Views and analysis

ASCO 2019 Preview – in partnership with Kantar

Mike Smith ASCO 2019, kantar, Oncology 0 Comment

ASCO’s 2019 conference is due to begin in just a few days’ time, highlighting the latest cutting edge

ASCO 2019 Preview – in partnership with Kantar

https://pharmaphorum.com/views-analysis-oncology/asco-2019-preview-partnership-kantar/

Oncology/ Views & Analysis/ Views and analysis

ASCO 2019 and the future of oncology

Mike Smith ASCO 2019, kantar, Oncology 0 Comment

The future of oncology is to be showcased at ASCO 2019 when the world’s leading cancer event returns

ASCO 2019 and the future of oncology

https://pharmaphorum.com/views-and-analysis/spotlight-asco-2019-future-oncology/

Trending

About Mike Smith

Posts by Mike Smith:

Building cell therapy leadership in Europe

9th EPP Life Sciences Pricing Forum

Building our own community for an ultra-rare disease

The Falsified Medicines Directive – truly an opportunity for pharma?

Spotlight on the future of generics

ASCO 2019 round-up

ASCO 2019 – Kantar takes a first look at interim data from the Phase 3 TITAN trial

ASCO 2019 Preview – in partnership with Kantar

ASCO 2019 and the future of oncology

Trending

About Mike Smith

Posts by Mike Smith:

Login